61996-32-5

Usage

Uses

Used in Pharmaceutical Industry:
N-(5-Methyl-thiazol-2-yl)-acetamide is used as a therapeutic agent for treating conditions such as gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome. It functions by inhibiting the production of stomach acid, thereby providing relief from symptoms associated with these conditions.
As a Proton Pump Inhibitor:
N-(5-Methyl-thiazol-2-yl)-acetamide is used as a proton pump inhibitor to reduce the amount of acid produced in the stomach. This is particularly beneficial for individuals suffering from conditions that involve excessive stomach acid, such as GERD and Zollinger-Ellison syndrome, as it helps to alleviate symptoms and promote healing of the affected areas.
In Acid-Reducing Medications:
N-(5-Methyl-thiazol-2-yl)-acetamide is used as an active ingredient in the production of acid-reducing medications. Its ability to decrease stomach acid levels makes it a valuable component in the development of pharmaceuticals aimed at treating acid-related disorders.

InChI:InChI=1/C6H8N2OS/c1-4-3-7-6(10-4)8-5(2)9/h3H,1-2H3,(H,7,8,9)

Upstream product

• 7305-71-7 5-methyl-2-thiazol-2-amine 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 144836-46-4 1-bromo-1-nitropropan-2-one 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR)

The present invention relates to bicyclic compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds. A-B-L-C (I)

Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study

Sirtuins are NAD+-dependent protein deacylases that cleave off acetyl but also other acyl groups from the ε-amino group of lysines in histones and other substrate proteins. Dysregulation of human Sirt2 (hSirt2) activity has been associated with the pathogenesis of cancer, inflammation, and neurodegeneration, which makes the modulation of hSirt2 activity a promising strategy for pharmaceutical intervention. The sirtuin rearranging ligands (SirReals) have recently been discovered by us as highly potent and isotype-selective hSirt2 inhibitors. Here, we present a well-defined structure-activity relationship study, which rationalizes the unique features of the SirReals and probes the limits of modifications on this scaffold regarding inhibitor potency. Moreover, we present a crystal structure of hSirt2 in complex with an optimized SirReal derivative that exhibits an improved in vitro activity. Lastly, we show cellular hyperacetylation of the hSirt2 targeted tubulin caused by our improved lead structure.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula (I): or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

QUINOLINE DERIVATIVES FOR TREATING CANCER

The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS

The invention concerns naphthyridine derivatives of Formula (I): or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, G1, G2, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders or disease states associated with angiogenesis and/or vascular permeability.

Reaction of 2-Aminothiazoles with Reagents containing a C-Halogen and a C=O Electrophilic Centre

Seven reagents of different types having in common a C-Hal and a C=O electrophilic centre have been used in a study of their reactions with 2-aminothiazoles.Three reagents, CHBrAc2 and ROCHBrCO2Et (R = Me, Ph), gave imidazothiazoles, thus providing useful routes to the 5-acetyl and 5-ethoxycarbonyl derivatives.Unexpectedly, the solvent (acetone) was involved in the reaction of the fourth reagent, CHBr(CO2Et)2, with 2-aminothiazole which led to 5,5-di(ethoxycarbonyl)-6,6-dimethyl-5,6-dihydroimidazothiazole (yield 81percent).With the last three reagents (AcCHBrNO2, BzCHBrCN and ICH2CO2C6H4NO2-p) the outcome was simpler, viz., the formation of 2-amidothiazoles.It is proposed that electrophilic attack by the endo-N of the 2-aminothiazole is the first step in all cases.This occurs at the C-Hal centre of the first four reagents and is followed by cyclisation to the exo-N.In the last three electrophiles the presence of the groups well suited to leaving as stabilised anions favours addition to the C=O group; the intermediates so formed subsequently isomerise to the more stable exo-N substituted products.